VivoSeq
Oncology

Non-Metastatic Castration-Resistant Prostate Cancer

1

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Non-metastatic Castration-resistant Prostate Cancer is an early-stage landscape with 1 program across 1 company. The most active players are Bayer. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Darolutamide

Bayer

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Not yet recruiting1 · 33%

Clinical Trials

Trial Activity

A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Recruiting·Bayer logoBayer·Approved·NCT05348876·50 enrolled
A Multicenter, Real-world Study Evaluating the Effectiveness of Darolutamide Plus ADT in Patients Progressing to nmCRPC After Bicalutamide Plus ADT Treatment During nmHSPC Stage
Not yet recruiting·Bayer logoBayer·N/A·NCT07538843·800 enrolled
Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients
Recruiting·Bayer logoBayer·N/A·NCT06334120·600 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)